SHIFT Newsroom · UK
Foundayo approved in the UK: what the orforglipron decision means
UK archive · Original report: 10 August 2026. The MHRA’s August 2026 decision covers weight management and type 2 diabetes. It does not by itself create NHS access or confirm private stock.
UK archive review · 13 September 2026. Original source: 10 August 2026. This article revisits a UK development; it is not a new announcement today.
The UK decision
On 10 August 2026, the MHRA authorised orforglipron, marketed as Foundayo, for weight management and type 2 diabetes in eligible adults. It is a prescription-only GLP-1 medicine taken as a daily tablet.
The regulator describes a tablet without food or water timing restrictions, with treatment escalated under prescribing instructions. That is a feature of this medicine's authorised use, not a reason to apply its instructions to another tablet or injection.
What did not follow automatically
At the time of the announcement, the MHRA said Foundayo was not available through the NHS. Regulatory approval, assessment for NHS use and commercial supply are different stages. None should be collapsed into a claim that everybody can now obtain it.
What readers should ask
If a treatment is being considered, ask the prescribing service to explain the indication, monitoring, possible side effects and whether the total care package fits your circumstances. A new option is still an individual clinical decision.
This report records the UK announcement without recommending a brand or confirming SHIFT availability. The MHRA lists gastrointestinal effects among common side effects and warns against unregulated sellers. Use the current patient leaflet and a registered prescribing service for medicine-specific advice.
What this means in the UK
UK readers should distinguish authorisation from current NHS access and a particular provider’s supply arrangements.
Known facts
- The MHRA authorised orforglipron in the UK on 10 August 2026 for weight management and type 2 diabetes.